CHAPTER 4
SECTION 5.1

## RADIONUCLIDE IMAGING PROCEDURE

ISSUE DATE: October 12, 1984

AUTHORITY: 32 CFR 199.4(b) and (c)

I. CPT PROCEDURE CODES

78000 - 78799, 78800 - 78999

## II. POLICY

A. Radionuclide imaging is covered when medically necessary and appropriate; however, the following procedures are seldom indicated and require special written justification:

- 1. 78070 Parathyroid Nuclear Imaging<sup>1</sup> Computerized tomography (CT) is superior to radionuclide parathyroid imaging, including its use with selenium-75 selenomethionine.
- 2. 78299 *GI Nuclear Procedure*<sup>1</sup> -Radionuclide liver function study with hepatobiliary agents, with probe technique When available, computer-assisted radionuclide liver function study is superior.
- 3. 78299 *GI Nuclear Procedure*<sup>1</sup> Radionuclide pancreas imaging Computerized tomography and ultrasound are superior to radionuclide pancreas imaging, including its use with selenium-75 selenomethionine.
- 4. 78299 *GI Nuclear Procedure*<sup>1</sup> Gastrointestinal fat absorption with radioiodinated triolein Surpassed by other studies.
- 5. 78704 *Imaging Renogram*<sup>1</sup> Radionuclide kidney imaging with function study (i.e., imaging renogram) When available, computer-assisted renal scintigraphy study is superior to radionuclide kidney imaging with function study, including its use with I-131 hippuran and external scintillation probes.
- B. Indium<sup>111</sup> Pentetreotide (Octreoscan) Scintigraphy is covered for the localization and monitoring of treatment of primary and metastatic neuroendocrine tumors.

<sup>&</sup>lt;sup>1</sup> CPT codes, descriptions and other data only are copyright 2004 American Medical Association. All rights reserved. Applicable FARS/DFARS Restrictions Apply to Government use.

III. EFFECTIVE DATE

June 1, 1994, for Octreoscan Scintigraphy.

- END -